Tune in as our team of global experts identifies and summarizes the key findings of the latest cardio-oncology studies during a half-hour virtual presentation and panel discussion. As cancer and cardiovascular care are constantly evolving, our insights and analysis empower viewers to seamlessly integrate the latest information into their clinical practice.
Cardio-Oncology Journal Club
FEATURED RECORDINGS
Filter
Prediction of mortality, bleeding, and ischemic events in patients with cancer and acute coronary syndrome: ONCO-ACS score with Florian Wenzl
Acute Coronary Syndrome management in cancer patients is challenging due to the complex interplay of mortality, bleeding and ischemic risk. The ONCO-ACS score leverages machine learning to provide an individualized…
April 24, 2026Sacubitril-Valsartan for Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin: The SARAH Trial with Marcely Bonatto
The clinical effects of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, on anthracycline-induced cardiotoxicity remain unknown. Experimental evidence suggests cardioprotective properties. This study evaluated the efficacy of sacubitril-valsartan in reducing cardiotoxicity in…
March 15, 2026Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy with Anthony Yu
Echocardiograms are recommended every 3 months to monitor for cancer therapy–related cardiac dysfunction (CTRCD) among patients treated with HER2-targeted therapy, despite increasing use of safer regimens associated with low CTRCD…
February 15, 2026Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer with Ana Barac
Breast cancer patients often receive cardiotoxic cancer therapy, and have an increased risk of cardiovascular mortality compared to the general population. In this study, investigators developed a cardiotoxicity risk prediction…
January 15, 2026Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE trial) with Christopher Booth
Exercise has been shown to reduce cancer recurrence and death rates in observational studies but definitive Level 1 data has been lacking. In the CHALLENGE phase 3 multi-center trial, investigators…
December 15, 2025Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer with Sara Hurvitz
Antibody drug conjugates (ADC) targeting ERBB2 positive breast cancer have improved outcomes, and may even hold potential for first-line indication in some patients. Cardiomyopathy rates with conventional ERBB2 targeting therapies…
November 9, 2025Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials with Soumyajit Roy and Avirup Guha
Statins are competitive inhibitors of cholesterol biosynthesis and additional derivatives of the mevalonate pathway. For this cohort study, the investigators conducted a pooled analysis of individual patient data from 2…
October 15, 2025SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes with Sarju Ganatra
Cancer treatments can lead to cancer therapy–related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is) can potentially prevent these cardiotoxic effects. This study sought to determine whether SGLT2i use is…
September 15, 2025Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism: API-CAT Trial with Isabelle Mahe
The API-CAT trial studied whether among active cancer patients with venous thromboembolism, treatment with a reduced oral anticoagulant dose is effective in preventing recurrent thromboembolic events and decreasing bleeding. Read…
August 15, 2025Preventing Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial with Erin Howden
Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. The investigators…
May 15, 2025










